UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 InfectionPRNewsWire • 08/20/21
Why Regeneron Pharmaceuticals (REGN) Isn't Done Growing Earnings YetZacks Investment Research • 08/19/21
Regeneron's Antibody Cocktail Authorized for Preventing COVID: Why It's Not a Big Deal for the StockThe Motley Fool • 08/14/21
Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 08/12/21
Regeneron Pharmaceuticals Inc. (REGN) CEO Leonard Schleifer on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/05/21
Sanofi - Regeneron's Libtayo/Chemo Treatment Improves Overall Survival First-Line Lung CancerBenzinga • 08/05/21
Regeneron Beats Street Estimates Big In Q2 As COVID-19 Antibody Boosts Topline, Cuts FY21 R&D Spend OutlookBenzinga • 08/05/21
Regeneron shares jump 3.3% premarket after earnings blow past estimates; COVID antibody sales total $2.59 billionMarket Watch • 08/05/21
Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancerGlobeNewsWire • 08/05/21
Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung CancerPRNewsWire • 08/05/21
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Prevent SARS-CoV-2 InfectionPRNewsWire • 08/04/21
Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMNZacks Investment Research • 08/04/21